Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Role of Protein Ubiquitination and HIF Signaling in the Evolution of Hypoxic Breast Cancer

Author(s): Suman Kumar Ray and Sukhes Mukherjee*

Volume 25, Issue 17, 2024

Published on: 23 February, 2024

Page: [2183 - 2185] Pages: 3

DOI: 10.2174/0113892010292219240212065544

Price: $65

Abstract

Alternations in protein ubiquitination along with hypoxia-inducible factor (HIF) signaling contribute to tumorigenesis and breast tumor advancement. Ubiquitination is an impulsive process, which is coordinately governed by E3 ligases and deubiquitinases (DUBs), that have come out as charismatic therapeutic targets. HIF expression, as well as the transcriptional process in malignancies, are frequently elevated, resulting in pitiable clinical outcomes. According to increasing research, multiple E3 ligases, in addition to UBDs work together to modulate HIF expression and activity, permitting breast cancer cells to make out a hypoxic milieu. On the other hand, hypoxia and HIF signaling regulate numerous E3 ligases as well as DUBs. Interpreting involved networks connecting E3 ligase, DUBS, and HIF will reveal profound mechanisms of physiological response to hypoxia and aid in the discovery of new molecular references for cancer management. The present state of knowledge about the entire kinship among E3 ligase, DUBs, and HIF signaling is reviewed here, emphasizing using E3 ligase or DUB inhibitors in breast cancer.

Next »
[1]
Wang, Y.; Li, G.; Deng, M.; Liu, X.; Huang, W.; Zhang, Y.; Liu, M.; Chen, Y. The multifaceted functions of RNA helicases in the adaptive cellular response to hypoxia: From mechanisms to therapeutics. Pharmacol. Ther., 2021, 221, 107783.
[2]
Ray, S.K.; Mukherjee, S. Targeting tumor hypoxia and hypoxia-inducible factors (HIFs) for the treatment of cancer- A story of transcription factors with novel approach in molecular medicine. Curr. Mol. Med., 2022, 22(3), 193-194.
[3]
Chen, Y.; Liu, M.; Niu, Y.; Wang, Y. Romance of the three kingdoms in hypoxia: HIFs, epigenetic regulators, and chromatin reprogramming. Cancer Lett., 2020, 495, 211-223.
[4]
Ray, S.K.; Mukherjee, S. Epigenetic reprogramming and landscape of transcriptomic interactions: Impending therapeutic interference of triple-negative breast cancer in molecular medicine. Curr. Mol. Med., 2022, 22(10), 835-850.
[5]
Semenza, G.L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol., 2014, 9, 47-71.
[6]
Sadanandom, A.; Bailey, M.; Ewan, R.; Lee, J.; Nelis, S. The ubiquitin-proteasome system: central modifier of plant signaling. New Phytol., 2012, 196, 13-28.
[7]
Ray, S.K.; Mukherjee, S. Imitating hypoxia and tumor microenvironment with immune evasion by employing three dimensional in vitro cellular models: Impressive tool in drug discovery. Recent Patents Anticancer Drug Discov., 2022, 17(1), 80-91.
[8]
Huang, Y.; Lin, D.; Taniguchi, C.M. Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? Sci. China Life Sci., 2017, 60(10), 1114-1124.
[9]
Mann, M.; Jensen, O.N. Proteomic analysis of post-translational modifications. Nat. Biotechnol., 2003, 21, 255-261.
[10]
Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem., 1998, 67, 425-479.
[11]
Wang, Y.; Liu, X.; Huang, W.; Liang, J.; Chen, Y. The intricate interplay between HIFs, ROS, and the ubiquitin system in the tumor hypoxic microenvironment. Pharmacol. Ther., 2022, 240, 108303.
[12]
Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J.M.; Lane, W.S.; Kaelin, W.G., Jr HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science, 2001, 292, 464-468.
[13]
Zhang, C.; Peng, Z.; Zhu, M.; Wang, P.; Du, X.; Li, X.; Liu, Y.; Jin, Y.; McNutt, M.A.; Yin, Y. USP9X destabilizes pVHL and promotes cell proliferation. Oncotarget, 2016, 7, 60519-60534.
[14]
Xu, Y.C.; Gu, Y.; Yang, J.Y.; Xi, K.; Tang, J.C.; Bian, J.; Cai, F.; Chen, L. RACK1 mediates the advanced glycation end product-induced degradation of HIF-1 alpha in nucleus pulposus cells via competing with HSP90 for HIF-1 alpha binding. Cell Biol. Int., 2021, 45, 1316-1326.
[15]
Koh, M.Y.; Darnay, B.G.; Powis, G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol. Cell. Biol., 2008, 28, 7081-7095.
[16]
Roe, J.S.; Kim, H.; Lee, S.M.; Kim, S.T.; Cho, E.J.; Youn, H.D. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol. Cell, 2006, 22, 395-405.
[17]
Mennerich, D.; Kubaichuk, K.; Kietzmann, T. DUBs, hypoxia, and cancer. Trends Cancer, 2019, 5, 632-653.
[18]
Ray, S.K.; Mukherjee, S. Altered expression of TRIM proteins-inimical outcome and inimitable oncogenic function in breast cancer with diverse carcinogenic hallmarks. Curr. Mol. Med., 2023, 23(1), 44-53.

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy